Mensah E, Tabrizchi R, Daneshtalab N
ACS Pharmacol Transl Sci. 2022; 5(11):1034-1049.
PMID: 36407955
PMC: 9667477.
DOI: 10.1021/acsptsci.2c00141.
Mohanan A, Gupta R, Dubey A, Jagtap V, Mandhare A, Gupta R
Int J Hypertens. 2012; 2011:751513.
PMID: 22235363
PMC: 3253485.
DOI: 10.4061/2011/751513.
Lukawski K, Jakubus T, Raszewski G, Czuczwar S
J Neural Transm (Vienna). 2010; 117(10):1161-6.
PMID: 20714908
DOI: 10.1007/s00702-010-0455-y.
Tuck M, Golub M, Eggena P, Sowers J, Maxwell M
West J Med. 1983; 139(2):190-203.
PMID: 18749429
PMC: 1010930.
SAMBHI M, Gavras H, Robertson J, Smith W
West J Med. 1993; 158(3):286-94.
PMID: 8460511
PMC: 1311755.
Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.
Heel R, Brogden R, Speight T, Avery G
Drugs. 1980; 20(6):409-52.
PMID: 7009133
DOI: 10.2165/00003495-198020060-00001.
Factors related to first dose hypotensive effect of captopril: prediction and treatment.
Hodsman G, Isles C, Murray G, Usherwood T, Webb D, Robertson J
Br Med J (Clin Res Ed). 1983; 286(6368):832-4.
PMID: 6403103
PMC: 1547159.
DOI: 10.1136/bmj.286.6368.832.
Angiotensin-converting enzyme inhibitors in the treatment of hypertension.
Johnston C, Arnolda L, Hiwatari M
Drugs. 1984; 27(3):271-7.
PMID: 6323123
DOI: 10.2165/00003495-198427030-00006.
Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.
Johnston C, Jackson B, Larmour I, Cubella R, Casley D
Br J Clin Pharmacol. 1984; 18 Suppl 2:233S-239S, 241S.
PMID: 6099738
PMC: 1463475.
DOI: 10.1111/j.1365-2125.1984.tb02602.x.
Captopril before and after spironolactone therapy in primary aldosteronism. Pathogenetic and therapeutical aspects.
Stimpel M, Vetter W, GROTH H, Greminger P, Vetter H
Klin Wochenschr. 1985; 63(8):361-3.
PMID: 3889485
DOI: 10.1007/BF01731655.
Effect of captopril on renin and blood pressure in cirrhosis.
Stanek B, Renner F, Sedlmayer A, Silberbauer K
Eur J Clin Pharmacol. 1987; 33(3):249-54.
PMID: 3319647
DOI: 10.1007/BF00637557.
[Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].
Schrader J, Schoel G, Scheler F
Klin Wochenschr. 1986; 64(15):695-700.
PMID: 3020311
DOI: 10.1007/BF01712054.
Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
Stumpe K, Overlack A, Kolloch R, Schatz J, Witte P, Pahnke K
Klin Wochenschr. 1986; 64(12):558-62.
PMID: 3016405
DOI: 10.1007/BF01735319.
The description and prediction of antihypertensive drug response: an individualised approach.
Donnelly R, MEREDITH P, Elliott H
Br J Clin Pharmacol. 1991; 31(6):627-34.
PMID: 1678270
PMC: 1368571.
DOI: 10.1111/j.1365-2125.1991.tb05584.x.
Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.
Burnier M, Biollaz J
Clin Pharmacokinet. 1992; 22(5):375-84.
PMID: 1505143
DOI: 10.2165/00003088-199222050-00004.
Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients.
Ferrier C, Ferrari P, Weidmann P, Keller U, Riesen W
Drugs. 1992; 44 Suppl 1:74-84.
PMID: 1283588
DOI: 10.2165/00003495-199200441-00014.
